Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Common Equity (2016 - 2026)

United Therapeutics' Common Equity history spans 17 years, with the latest figure at $7.1 billion for Q4 2025.

  • On a quarterly basis, Common Equity rose 10.12% to $7.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 billion, a 10.12% increase, with the full-year FY2025 number at $7.1 billion, up 10.12% from a year prior.
  • Common Equity hit $7.1 billion in Q4 2025 for United Therapeutics, up from $6.6 billion in the prior quarter.
  • Over the last five years, Common Equity for UTHR hit a ceiling of $7.2 billion in Q2 2025 and a floor of $3.4 billion in Q1 2021.
  • Historically, Common Equity has averaged $5.3 billion across 5 years, with a median of $5.4 billion in 2023.
  • Biggest five-year swings in Common Equity: grew 4.19% in 2024 and later increased 27.52% in 2025.
  • Tracing UTHR's Common Equity over 5 years: stood at $4.0 billion in 2021, then increased by 21.16% to $4.8 billion in 2022, then increased by 24.77% to $6.0 billion in 2023, then rose by 7.67% to $6.4 billion in 2024, then rose by 10.12% to $7.1 billion in 2025.
  • Business Quant data shows Common Equity for UTHR at $7.1 billion in Q4 2025, $6.6 billion in Q3 2025, and $7.2 billion in Q2 2025.